Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) received a $9.00 target price from equities researchers at HC Wainwright in a research note issued to investors on Wednesday. The brokerage presently has a “buy” rating on the biotechnology company’s stock. HC Wainwright’s price target indicates a potential upside of 80.00% from the company’s previous close.

Separately, BidaskClub cut shares of Pieris Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Wednesday, July 26th. Four research analysts have rated the stock with a buy rating, The stock has an average rating of “Buy” and an average price target of $9.00.

Shares of Pieris Pharmaceuticals (PIRS) traded down 1.96% during midday trading on Wednesday, reaching $5.00. The company had a trading volume of 340,930 shares. The firm’s market capitalization is $221.54 million. Pieris Pharmaceuticals has a one year low of $1.30 and a one year high of $6.58. The company has a 50 day moving average price of $5.64 and a 200-day moving average price of $5.64.

COPYRIGHT VIOLATION WARNING: This piece was originally posted by Watch List News and is the property of of Watch List News. If you are viewing this piece on another domain, it was illegally copied and republished in violation of United States & international trademark & copyright legislation. The correct version of this piece can be accessed at https://www.watchlistnews.com/pieris-pharmaceuticals-inc-pirs-given-a-9-00-price-target-by-hc-wainwright-analysts/1644169.html.

In other Pieris Pharmaceuticals news, Director James A. Geraghty bought 10,000 shares of the stock in a transaction on Thursday, August 17th. The shares were acquired at an average price of $4.82 per share, with a total value of $48,200.00. Following the acquisition, the director now directly owns 10,000 shares of the company’s stock, valued at approximately $48,200. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, insider Allan Reine bought 65,000 shares of the stock in a transaction on Thursday, August 17th. The shares were acquired at an average cost of $4.82 per share, for a total transaction of $313,300.00. Following the acquisition, the insider now directly owns 45,000 shares in the company, valued at $216,900. The disclosure for this purchase can be found here. Insiders own 4.05% of the company’s stock.

A number of hedge funds have recently modified their holdings of the business. Voya Investment Management LLC purchased a new position in shares of Pieris Pharmaceuticals during the 2nd quarter valued at $100,000. State of Wisconsin Investment Board purchased a new position in shares of Pieris Pharmaceuticals during the 2nd quarter valued at $132,000. The Manufacturers Life Insurance Company grew its position in shares of Pieris Pharmaceuticals by 1,106.3% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 31,785 shares of the biotechnology company’s stock valued at $161,000 after purchasing an additional 29,150 shares in the last quarter. Acadian Asset Management LLC purchased a new position in shares of Pieris Pharmaceuticals during the 2nd quarter valued at $162,000. Finally, Rhumbline Advisers purchased a new position in shares of Pieris Pharmaceuticals during the 2nd quarter valued at $184,000. 50.50% of the stock is currently owned by institutional investors and hedge funds.

Pieris Pharmaceuticals Company Profile

Pieris Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s pipeline includes immuno-oncology multi-specifics tailored for the tumor micro-environment, an inhaled Anticalin to treat uncontrolled asthma and a half-life-optimized Anticalin to treat anemia. Its Anticalins proteins are a class of low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins typically found in blood plasma and other bodily fluids.

Receive News & Ratings for Pieris Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pieris Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.